{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Safety+Control&page=22", "query": { "intervention": "Safety Control", "page": 22 }, "page_size": 10 }, "pagination": { "page": 22, "page_size": 10, "total_count": 14113, "total_pages": 1412, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Safety+Control&page=23&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Safety+Control&page=21&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-30T17:57:48.833Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02186665", "title": "Plaque Psoriasis Study in Pediatric Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Plaque Psoriasis" ], "interventions": [ { "name": "calcitriol ointment", "type": "DRUG" }, { "name": "placebo comparator", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Galderma R&D", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "12 Years", "sex": "ALL", "summary": "2 Years to 12 Years" }, "enrollment_count": 19, "start_date": "2014-07", "completion_date": "2016-01", "has_results": true, "last_update_posted_date": "2021-02-18", "last_synced_at": "2026-10-30T17:57:48.833Z", "location_count": 12, "location_summary": "Beverly Hills, California • Sacramento, California • Louisville, Kentucky + 9 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Jackson", "state": "Mississippi" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02186665" }, { "nct_id": "NCT05531565", "title": "A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Subacute Cutaneous Lupus Erythematosus", "Chronic Cutaneous Lupus Erythematosus" ], "interventions": [ { "name": "Litifilimab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 450, "start_date": "2022-09-13", "completion_date": "2027-12-14", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-30T17:57:48.833Z", "location_count": 62, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 52 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05531565" }, { "nct_id": "NCT02927067", "title": "A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cytomegalovirus (CMV)" ], "interventions": [ { "name": "Maribavir", "type": "DRUG" }, { "name": "Valganciclovir", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 553, "start_date": "2017-04-14", "completion_date": "2022-07-01", "has_results": true, "last_update_posted_date": "2023-03-03", "last_synced_at": "2026-10-30T17:57:48.833Z", "location_count": 28, "location_summary": "Birmingham, Alabama • Los Angeles, California • Stanford, California + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02927067" }, { "nct_id": "NCT03732807", "title": "PF-06651600 for the Treatment of Alopecia Areata", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Alopecia Areata" ], "interventions": [ { "name": "PF-06651600 Induction Dose", "type": "DRUG" }, { "name": "PF-06651600 Maintenance Dose #1", "type": "DRUG" }, { "name": "PF-06651600 Maintenance Dose #2", "type": "DRUG" }, { "name": "PF-06651600 Maintenance Dose #3", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 718, "start_date": "2018-12-03", "completion_date": "2021-06-24", "has_results": true, "last_update_posted_date": "2022-02-24", "last_synced_at": "2026-10-30T17:57:48.833Z", "location_count": 46, "location_summary": "Birmingham, Alabama • Beverly Hills, California • Irvine, California + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03732807" }, { "nct_id": "NCT04824092", "title": "Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diffuse Large B-cell Lymphoma" ], "interventions": [ { "name": "Tafasitamab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Tafasitamab placebo", "type": "DRUG" }, { "name": "Lenalidomide placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 899, "start_date": "2021-05-11", "completion_date": "2027-11-01", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-10-30T17:57:48.833Z", "location_count": 47, "location_summary": "Daphne, Alabama • Anaheim, California • Clovis, California + 44 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Clovis", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Harbor City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04824092" }, { "nct_id": "NCT00200434", "title": "A Study of the Efficacy and Safety of Nebivolol Added to Existing Antihypertensive Treatment in Patients With Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "Nebivolol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mylan Bertek Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 600, "start_date": "2002-10", "completion_date": "2003-10", "has_results": false, "last_update_posted_date": "2005-09-20", "last_synced_at": "2026-10-30T17:57:48.833Z", "location_count": 1, "location_summary": "Morgantown, West Virginia", "locations": [ { "city": "Morgantown", "state": "West Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00200434" }, { "nct_id": "NCT04432298", "title": "Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Pamrevlumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyntra Bio", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "40 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "40 Years to 85 Years" }, "enrollment_count": 22, "start_date": "2020-06-20", "completion_date": "2021-03-22", "has_results": true, "last_update_posted_date": "2022-07-18", "last_synced_at": "2026-10-30T17:57:48.833Z", "location_count": 4, "location_summary": "Detroit, Michigan • Greensboro, North Carolina • Philadelphia, Pennsylvania", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Greensboro", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04432298" }, { "nct_id": "NCT02954978", "title": "Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Parkinson Disease", "Parkinsons Disease With Dementia" ], "interventions": [ { "name": "Placebo Oral Capsule", "type": "DRUG" }, { "name": "Nilotinib 150mg oral capsule [Tasigna]", "type": "DRUG" }, { "name": "Nilotinib 300mg oral capsule [Tasigna]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "40 Years to 90 Years" }, "enrollment_count": 75, "start_date": "2017-01", "completion_date": "2020-07", "has_results": true, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-10-30T17:57:48.833Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02954978" }, { "nct_id": "NCT03796676", "title": "JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "PF-04965842", "type": "DRUG" }, { "name": "PF04965842", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "12 Years to 17 Years" }, "enrollment_count": 287, "start_date": "2019-02-18", "completion_date": "2020-04-08", "has_results": true, "last_update_posted_date": "2022-04-13", "last_synced_at": "2026-10-30T17:57:48.833Z", "location_count": 52, "location_summary": "Birmingham, Alabama • Madera, California • Mission Viejo, California + 31 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Madera", "state": "California" }, { "city": "Mission Viejo", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Doral", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03796676" }, { "nct_id": "NCT03523117", "title": "Multicenter Randomized Active-controlled Study to Investigate Efficacy & Safety of IV FCM in Pediatric Patients With IDA", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Iron Deficiency Anemia" ], "interventions": [ { "name": "Ferric carboxymaltose", "type": "DRUG" }, { "name": "Ferrous Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "American Regent, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Year to 17 Years" }, "enrollment_count": 79, "start_date": "2019-01-31", "completion_date": "2021-01-29", "has_results": true, "last_update_posted_date": "2022-06-22", "last_synced_at": "2026-10-30T17:57:48.833Z", "location_count": 16, "location_summary": "Little Rock, Arkansas • Doral, Florida • Miami, Florida + 10 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Doral", "state": "Florida" }, { "city": "Doral", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03523117" } ] }